Quest Diagnostics Campfire and child in canoe

Easy-to-use, comprehensive, turn-key program

Quest Diagnostics understands how important it is for camps to provide fun, camaraderie, and time together during the summer. We can help you develop solutions for testing and supply other mitigation strategies that will allow your campers and staff to continue having adventures together.

Our Back to Camp program offers:

Magnifying glass icon

Standardized protocols designed to quickly identify asymptomatic campers and staff

Step by step icon

Step-by-step program implementation guide

Support icon

Video training and expert support

Videos icon

Educational videos and materials for parents and campers

Results icon

Rapid, online results reporting for the pod-pooled sample and confirmatory testing to the individual

Contact us to get started

Fill out the form below to be contacted by one of our representatives and learn how we can work together to help your campers and staff.









Our 2-step testing strategy

1

Weekly screening for everyone

Doctor icon

High-quality "pod-pooled" molecular swab tests can rapidly sample camp populations to reduce the likelihood of asymptomatic spread.

2

Follow-up testing for positive pod results

COVID virus icon

For confirmatory testing, members of positive pods use a self-collection kit that is sent to a lab and tested to help determine next steps.

What is pod-pooled testing?

Pod-pooled testing refers to surveillance testing at the group level to uncover any current infections. A collection of up to ten samples, in this case nasal swabs, is tested at the group level instead of the individual level. Because testing is performed on a pooled sample, testing is extremely cost-effective, and may be ideal for camp environments, offering quick results to assess risk.

Pod-pooled testing is for surveillance only. Positive pods require follow-up confirmatory diagnostic testing at the individual level.

How does the program work?

Campers will be instructed on how to use a simple and safe method to test themselves. They will collect their own samples via a simple nose swab. Those samples, along with those from their fellow campers and staff, will be “pod-pooled” to conduct the lab tests and return the results quickly.

Prep test icon

Prepare your camp

  • We educate parents on testing program and train staff
  • Collect parent opt-in for testing/collecting consent
  • Develop testing pods
Gears icon

Quest prepares your tests

  • We generate testing requisitions and labels
  • Then assemble Back to Camp testing boxes
  • And deliver testing boxes to camp
Nose swab icon

Collect everyone's test samples

  • Staff instructs and observes campers on self-swabbing
  • Campers give swab to observer
  • Observer places all swabs inside single tubes
  • Tubes collected at single point within camp
Test tubes icon

Quest processes the tests

  • We arrange for sample pickup and transport to Quest
  • Our lab performs pod-pooled test
  • Pod-level results made available to camp
Test results icon

You get your results

  • If surveillance pod-level testing is positive, confirmatory diagnostic testing is offered
  • For positive cases, initiate the necessary treatment, isolation, and contract tracing protocols
  • These steps may vary depending on state and local guidelines

Resources

Download detailed program information to learn how our testing strategy helps your campers and staff keep having summer fun.

FAQs

K-12 support Brochure Download

Quest is the leader in COVID-19 testing

Quest has processed tens of millions of COVID-19 tests to date, completing more testing nationwide than any other lab. We are constantly expanding and improving our testing capacity across the country. And our fast, accurate results empower you to make better health decisions for your camp.

Contact us today to begin your Back to Camp program.

Get Started

Explore our other testing programs

Testing Statements

  • No laboratory test is 100% accurate; the ability of a test to perform according to its specifications is subject to a number of factors including specimen handling, stability, timing of the specimen collection in relation to onset of the infection, and the instrumentation and system on which the test is performed.
  • The symptoms of COVID-19 may at times mimic other illness such as influenza and the common cold. It is important that those with symptoms are tested for the correct illness, and, where antigen testing is performed, that positive results in asymptomatic persons be sent for further confirmatory tests and medical consultation.
  • The self-collection kit is intended for surveillance purposes, and is not intended for screening or diagnostic uses subject to FDA regulation. This test should be used on a population-based level and should not be used by healthcare providers for patient care.
  • The cobas SARS-CoV-2 & Influenza A/B Test and the Quest SARS-CoV-2 RT-PCR test and other molecular tests (“Tests”) have not been FDA cleared or approved.
  • The Tests have been authorized by the FDA under an EUA for use by laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform moderate and high complexity tests. The Roche test has been authorized only for the detection of RNA from SARS-CoV-2 virus, Influenza A virus, and Influenza B virus and not any other viruses or pathogens.
  • The Roche test is only authorized for the duration of the declaration that circumstances exist justifying the authorized of the emergency use of in vitro diagnostics for detection and differentiation of SARS-CoV-2 virus, Influenza A, and Influenza B under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorized is terminated or revoked sooner.
  • The Quest test and other molecular tests been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens.
  • The Quest test and other molecular tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.